{"nctId":"NCT00546052","briefTitle":"A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)","startDateStruct":{"date":"2005-09-01","type":"ACTUAL"},"conditions":["Hypertension","Metabolic Disorder"],"count":1738,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: losartan potassium (+) hydrochlorothiazide"]}],"interventions":[{"name":"losartan potassium (+) hydrochlorothiazide","otherNames":["Cozaar/Hyzaar"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* An Adult Patient (At Least 18 Years Of Age) With A Clinical Identification Of The Metabolic Syndrome Using The IDF Definition:\n\n  * abdominal (central) obesity as defined by the waist circumference in men of \\> 102 cm and women of \\> 88 cm or a BMI equal or greater than 30 kg/m2\n\nand untreated hypertension with bp equal or greater than 140/90 mm Hg but bp \\< 180/110 mm Hg\n\nor a patient receiving one or two antihypertensive agent(s) (diuretics, ace inhibitors, angiotensin ii receptor blockers, calcium channel blockers and beta-blockers will need to be discontinued) and whose blood pressure is not controlled:\n\n* bp equal or greater than 140/90 mm Hg but equal or less than 160/100 mm Hg\n\nor a patient whose hypertension is controlled (\\< 140/90 mm hg) with a single anti-hypertensive agent (diuretics, ace inhibitors, and angiotensin II receptor blockers, calcium channel blockers and beta-blockers will need to be discontinued) but who is unsatisfied or experiencing side effects warranting a discontinuation of the previous treatment and at one of the following:\n\n* Fasting plasma glucose equal or greater than 5.6 mmol/L and \\< 7.0 mmol/L\n* Triglycerides \\> 1.7 mmol/L or specific treatment for this lipid abnormality\n* HDL-c in men \\< 0.9 mmol/L and in women \\< 1.1 mmol/L or specific treatment for this lipid abnormality\n\nExclusion Criteria:\n\n* A Patient With A Diagnosis Of Type II Diabetes Defined As Fasting Blood Glucose Level Equal Or Greater Than 7.0 Mmol/L Or A 2hpg In A 75-G OGTT Equal Or Greater Than 11.1 Mol/L Or Using Any Anti-Hyperglycemic Agents\n* Known Secondary Hypertension Of Any Aetiology (E.G., Uncorrected Renal Artery Stenosis, Malignant Hypertension, Or Hypertensive Encephalopathy)\n* Patient Intolerant To Any Component Of Losartan 50 Mg / Losartan 100 Mg / Losartan 100 Mg + Hctz 12.5 Mg / Losartan 100 Mg + Hctz 25 Mg Or With A Documented History Of Angioedema\n* Patient With Confirmed Clinically Significant Renal Or Hepatic Dysfunction And/Or Electrolyte Imbalance On The Basis Of The Case History Or A Recent Laboratory Test (Serum Creatinine \\> 130 Mmol/L Or Creatinine Clearance \\< 45 Ml/Min, Ast \\> 2 Times Above The Normal Range, Alt \\> 2 Times Above The Normal Range, Serum Potassium \\< 3.5 Or \\> 5.5 Meq/L)\n* Patient With Symptomatic Heart Failure (Classes 3 And 4)\n* Patient With A Prior Myocardial Infarction Or Stroke Within The Last 6 Months\n* Patient Who Has Undergone Percutaneous Coronary Angioplasty Or Coronary Artery Bypass Within The Last 3 Months\n* Pregnant Woman Or A Woman Of Childbearing Potential","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Hemoglobin A1c Between 52 Weeks and Baseline","description":"Absolute Change in Hemoglobin A1c between 52 week measurement and baseline value.","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.62"}]}]}]},{"type":"PRIMARY","title":"Change in Fasting Blood Glucose Between Baseline and 52 Weeks Assessments","description":"Absolute Change in Fasting Blood Glucose Measurements between Baseline and 52 week assessments.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.74"}]}]}]},{"type":"SECONDARY","title":"Target Blood Pressure","description":"Target Blood Pressure defined as Systolic Blood Pressure/Diastolic Blood Pressure â‰¤ 140/90 mm Hg at 52 weeks","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1200","spread":null},{"groupId":"OG001","value":"1200","spread":null},{"groupId":"OG002","value":"1200","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"538","spread":null},{"groupId":"OG001","value":"514","spread":null},{"groupId":"OG002","value":"311","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure Between Baseline and 52 Week Assessments","description":"Absolute change in Systolic Blood Pressure between baseline and 52 week assessments.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.95","spread":"13.34"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure Between Baseline and 52 Week Assessments","description":"Absolute change in Diastolic Blood Pressure between baseline and 52 week assessments.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.84","spread":"8.93"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Waist Circumference Between Baseline and 52 Week Assessments","description":"Absolute change in Waist Circumference between baseline and 52 week assessments","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.28","spread":"5.44"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Body Mass Index Between Baseline and 52 Week Assessments","description":"Absolute change in Body Mass Index Baseline and 52 week assessments","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.3","spread":"5.20"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change in Low Density Lipoprotein-C Between Baseline and 52 Week Assessments","description":"Percent Change in LDL-C Between Baseline and 52 week assessments: 100% x \\[(LDL-C 52 Weeks - LDL-C Baseline) / (LDL-C Baseline)\\].","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.49","spread":"32.10"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change in High Density Lipoprotein-C Between Baseline and 52 Week Assessments","description":"Percent Change in HDL-C Between Baseline and 52 week assessments: 100% x \\[(HDL-C 52 Weeks - HDL-C 52 Baseline) / (HDL-C Baseline)\\].","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"17.96"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change in Triglycerides Between Baseline and 52 Week Assessments","description":"Percent Change in Triglycerides Between Baseline and 52 week assessments: 100% x \\[(Triglycerides 52 Weeks - Triglycerides Baseline) / (Triglycerides Baseline)\\].","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.09","spread":"43.54"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change in Total Cholesterol Between Baseline and 52 Week Assessments","description":"Percent Change in Total Cholesterol Between Baseline and 52 week assessments: 100% x \\[(Total Cholesterol 52 weeks - Total Cholesterol Baseline) / (Total Cholesterol Baseline)\\].","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.98","spread":"16.97"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Absolute Change in Uric Acid Between Baseline and 52 Week Assessments","description":"Absolute Change in Uric Acid Between Baseline and 52 week assessments: Uric Acid 52 weeks - Uric Acid Baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.17","spread":"63.84"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Absolute Change in C Reactive Protein Between Baseline and 52 Week Assessments","description":"Absolute Change in C Reactive Protein Between Baseline and 52 week assessments: C Reactive Protein 52 weeks - C Reactive Protein Baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.36","spread":"8.66"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":35,"n":1714},"commonTop":["Type 2 diabetes mellitus","Dizziness","Bronchitis","Osteoarthritis","Headache"]}}}